Related Experiment Video

Updated: May 9, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Molecular mechanism of SLC5A8 inactivation in breast cancer

Selvakumar Elangovan1, Rajneesh Pathania, Sabarish Ramachandran

  • 1Departments of Biochemistry and Molecular Biology.

Molecular and Cellular Biology
|August 7, 2013
PubMed

Insights

The tumor suppressor SLC5A8 is silenced by oncogenic HRAS in breast cancer. Reactivating SLC5A8 may offer a new therapeutic strategy for breast cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • SLC5A8 is a potential tumor suppressor inactivated in over 10 cancer types.
  • The mechanisms of SLC5A8 inactivation and its role in tumor growth are not fully understood.

Purpose of the Study:

  • To identify the oncogenic signaling pathway responsible for SLC5A8 inactivation.
  • To elucidate the functional significance of SLC5A8 loss in mammary tumor development.

Main Methods:

  • Investigated HRAS(G12V) as a mediator of SLC5A8 silencing via DNMT1 in cell lines and mouse models.
  • Assessed the impact of Slc5a8 loss on cancer-initiating stem cells, mammary tumorigenesis, and metastasis.
  • Examined the protective effects of Slc5a8 overexpression and DNA methylation inhibitors against HRAS-driven tumors.

Main Results:

  • Oncogenic HRAS (HRAS(G12V)) silences SLC5A8 through DNMT1 in mammary epithelial cells and tumors.
  • Loss of Slc5a8 promotes cancer stem cell formation, mammary tumor growth, and lung metastasis in an HRAS-driven model.
  • Overexpression of Slc5a8 or DNA methylation inhibition protects against HRAS-driven mammary tumors.

Conclusions:

  • SLC5A8 acts as a tumor suppressor in mammary glands, with its silencing mediated by oncogenic HRAS.
  • Reactivating SLC5A8 expression pharmacologically presents a potential therapeutic strategy for breast cancer.

More Related Videos

Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples07:03

Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples

Published on: October 2, 2020

Related Concept Videos

Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...